CN110167637B - 3-羟基丁酸甘油酯用于偏头痛症状管理 - Google Patents

3-羟基丁酸甘油酯用于偏头痛症状管理 Download PDF

Info

Publication number
CN110167637B
CN110167637B CN201780078046.7A CN201780078046A CN110167637B CN 110167637 B CN110167637 B CN 110167637B CN 201780078046 A CN201780078046 A CN 201780078046A CN 110167637 B CN110167637 B CN 110167637B
Authority
CN
China
Prior art keywords
hydroxybutyrate
glycerol
migraine
mono
fatty acyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201780078046.7A
Other languages
English (en)
Chinese (zh)
Other versions
CN110167637A (zh
Inventor
萨米·哈希姆
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Neuroenergy Ventures Inc
Original Assignee
Neuroenergy Ventures Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neuroenergy Ventures Inc filed Critical Neuroenergy Ventures Inc
Publication of CN110167637A publication Critical patent/CN110167637A/zh
Application granted granted Critical
Publication of CN110167637B publication Critical patent/CN110167637B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A61K31/231—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms having one or two double bonds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
CN201780078046.7A 2016-12-23 2017-11-30 3-羟基丁酸甘油酯用于偏头痛症状管理 Active CN110167637B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US15/389,828 US20180177753A1 (en) 2016-12-23 2016-12-23 Glyceryl 3-hydroxybutyrates for migraine symptom management
US15/389,828 2016-12-23
PCT/US2017/063832 WO2018118369A1 (en) 2016-12-23 2017-11-30 Glyceryl 3-hydroxybutyrates for migraine symptom management

Publications (2)

Publication Number Publication Date
CN110167637A CN110167637A (zh) 2019-08-23
CN110167637B true CN110167637B (zh) 2023-03-14

Family

ID=62624821

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780078046.7A Active CN110167637B (zh) 2016-12-23 2017-11-30 3-羟基丁酸甘油酯用于偏头痛症状管理

Country Status (13)

Country Link
US (2) US20180177753A1 (cg-RX-API-DMAC7.html)
EP (1) EP3558458B1 (cg-RX-API-DMAC7.html)
JP (1) JP7108320B2 (cg-RX-API-DMAC7.html)
KR (1) KR102390608B1 (cg-RX-API-DMAC7.html)
CN (1) CN110167637B (cg-RX-API-DMAC7.html)
BR (1) BR112019012431A2 (cg-RX-API-DMAC7.html)
CA (1) CA3046350C (cg-RX-API-DMAC7.html)
ES (1) ES2962879T3 (cg-RX-API-DMAC7.html)
IL (1) IL267540B (cg-RX-API-DMAC7.html)
MX (1) MX389468B (cg-RX-API-DMAC7.html)
MY (1) MY190308A (cg-RX-API-DMAC7.html)
PT (1) PT3558458T (cg-RX-API-DMAC7.html)
WO (1) WO2018118369A1 (cg-RX-API-DMAC7.html)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11241403B2 (en) 2016-03-11 2022-02-08 Axcess Global Sciences, Llc Beta-hydroxybutyrate mixed salt compositions and methods of use
US11103470B2 (en) 2017-11-22 2021-08-31 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
US11806324B2 (en) 2018-04-18 2023-11-07 Axcess Global Sciences, Llc Beta-hydroxybutyric acid compositions and methods for oral delivery of ketone bodies
US11944598B2 (en) 2017-12-19 2024-04-02 Axcess Global Sciences, Llc Compositions containing s-beta-hydroxybutyrate or non-racemic mixtures enriched with the s-enatiomer
US12109182B2 (en) 2016-04-19 2024-10-08 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
US10925843B2 (en) 2018-04-18 2021-02-23 Axcess Global Sciences, Llc Compositions and methods for keto stacking with beta-hydroxybutyrate and acetoacetate
US11202769B2 (en) 2017-11-22 2021-12-21 Axcess Global Sciences, Llc Ketone body esters of s-beta-hydroxybutyrate and/or s-1,3-butanediol for modifying metabolic function
US12329734B2 (en) 2017-12-19 2025-06-17 Axcess Global Sciences, Llc Use of S-beta-hydroxybutyrate compounds for induction and maintenance of flow
US12496283B2 (en) 2016-04-19 2025-12-16 Axcess Global Sciences, Llc Administration of R-beta-hydroxybutyrate and related compounds in humans
DK3558280T3 (da) 2016-12-21 2023-08-21 Univ Kinderspital Beider Basel Forebyggelse og behandling af migræne
US10376528B2 (en) 2017-03-10 2019-08-13 Tecton Group, Llc Composition comprising ketone body and nicotinamide adenine dinucleotide modulator and methyl donor
GB201715654D0 (en) 2017-09-27 2017-11-08 Tdeltas Ltd Method of treatment
US12090129B2 (en) 2017-11-22 2024-09-17 Axcess Global Sciences, Llc Non-racemic beta-hydroxybutyrate compounds and compositions enriched with the R-enantiomer and methods of use
EP3880650B1 (de) * 2019-01-17 2023-09-06 KetoLipix Therapeutics GmbH Verfahren zur herstellung von struktureinheiten auf basis von glyceriden von hydroxycarbonsäuren enthaltenden lipiden
CN113329990B (zh) * 2019-01-17 2024-06-07 凯托利皮克斯治疗有限责任公司 羟基羧酸甘油酯的生产方法
BR112021017954A2 (pt) 2019-03-14 2021-11-16 Neuroenergy Ventures Inc Formulação de mascaramento de sabor para compostos de corpo cetônico
US12472200B2 (en) 2019-05-15 2025-11-18 Axcess Global Sciences, Llc Autobiotic compositions and method for promoting healthy gut microbiome
WO2020242478A1 (en) * 2019-05-30 2020-12-03 Neuroenergy Ventures, Inc. Glyceryl tris (beta-hydroxybutyrate) and neuronal transient ischemic attacks
US20250197566A1 (en) * 2019-06-12 2025-06-19 Ioi Oleo Gmbh Process for preparing polyol-based esters of acyl-capped hydroxy carboxylic acids
US11969430B1 (en) 2023-03-10 2024-04-30 Axcess Global Sciences, Llc Compositions containing paraxanthine and beta-hydroxybutyrate or precursor for increasing neurological and physiological performance
US11950616B2 (en) 2019-06-21 2024-04-09 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
US12167993B2 (en) 2019-06-21 2024-12-17 Axcess Global Sciences, Llc Non-vasoconstricting energy-promoting compositions containing ketone bodies
IT201900018491A1 (it) * 2019-10-10 2021-04-10 Dr Schaer S P A Procedimento di purificazione del tris-(3-idrossibutirrato)-gliceril estere
IT201900018488A1 (it) * 2019-10-10 2021-04-10 Dr Schaer S P A Procedimento di preparazione del tris-(3-idrossibutirrato)-gliceril estere
US12186297B2 (en) 2020-08-26 2025-01-07 Axcess Global Sciences, Llc Compositions and methods for increasing lean-to-fat mass ratio
AU2022387742A1 (en) * 2021-11-12 2024-06-27 Arxada Ag Polyol-derived compounds
US20250002446A1 (en) * 2021-11-26 2025-01-02 Arxada Ag Acetoacetate Based Ketals
US20240299548A1 (en) * 2022-01-18 2024-09-12 Today, Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
US12023382B2 (en) 2022-01-18 2024-07-02 Today Inc. Molecules, formulations, and methods for nutritional support of athletes, patients, and others
WO2024083889A1 (en) 2022-10-18 2024-04-25 Arxada Ag Polyol-derived compounds
WO2025074001A2 (en) 2023-10-05 2025-04-10 Arxada Ag Enzymatic reduction of acetoacetate
WO2025196156A1 (en) 2024-03-20 2025-09-25 Arxada Ag Continuous hydrogenation process of acetoacetate esters
WO2025224319A1 (en) 2024-04-25 2025-10-30 Arxada Ag Reduction of acetoacetate esters in the presence of amines

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0420856D0 (en) * 2004-09-20 2004-10-20 Ketocytonyx Inc Cns modulators
HUE035852T2 (en) 2006-04-03 2018-05-28 Accera Inc Use of ketogen compounds to treat memory decline
WO2008005818A1 (en) * 2006-06-30 2008-01-10 Stepan Co Glyceride esters for the treatment of diseases associated with reduced neuronal metabolism of glucose
BRPI1005372A2 (pt) * 2009-01-24 2018-03-06 Phytopharm Plc metodo de indução da homeostase- regulada de fatores neurotroficos agente; composição; e; uso de um ou mais agentes selecionados de saponinas esteroidais de a/b-cis furostano, furosteno espirostano e espirosteno, e as suas formas de eter, cetona e glicosiladas
CA2873057C (en) 2011-05-09 2020-02-25 University Of South Florida The use of ketone esters for prevention of cns oxygen toxicity
US20140072654A1 (en) 2011-12-23 2014-03-13 Savind, Inc. Cancer with metabolic therapy and hyperbaric oxygen
FR2997302B1 (fr) * 2012-10-29 2015-02-06 Assist Publ Hopitaux De Paris Prevention et traitement des deficits en pyruvate deshydrogenase
ES2752030T3 (es) 2012-11-05 2020-04-02 Us Health Cuerpos cetónicos para proteger los tejidos del daño por radiación ionizante
EP2925308B1 (en) 2012-11-28 2019-12-25 University Of South Florida Targeting cancer with metabolic therapy and hyperbaric oxygen
WO2014153416A1 (en) 2013-03-19 2014-09-25 University Of South Florida Compositions and methods for producing elevated and sustained ketosis
GB201314127D0 (en) * 2013-08-07 2013-09-18 Tdeltas Ltd Ketone body and ketone body ester for reducing muscle breakdown
EP3549928B1 (en) 2014-01-13 2021-09-22 University of South Florida Methods of sustaining dietary ketosis and its effects on muscle fatigue
US20160078782A1 (en) * 2014-09-17 2016-03-17 The Trustees Of Boston College Glucose Ketone Index for MetabolicTherapy
US9364456B1 (en) 2015-06-30 2016-06-14 University Of South Florida Ketone esters for treatment of angelman syndrome
WO2017011294A1 (en) 2015-07-10 2017-01-19 Cognate Nutritionals, Inc. Prophylaxis and mitigation of migraine headaches using medium chain triglycerides, ketone esters, and other ketogenic sources
US10292952B2 (en) 2016-03-11 2019-05-21 Axcess Global Sciences, Llc Mixed salt compositions for maintaining or restoring electrolyte balance while producing elevated and sustained ketosis
US10376482B2 (en) 2016-04-03 2019-08-13 Franco Cavaleri Butyrate and beta-hydroxybutyrate compositions
SG11201809211QA (en) 2016-04-19 2018-11-29 Keto Patent Group Inc Administration of butyrate, beta-hydroxybutyrate, and related compounds in humans
WO2018009208A1 (en) 2016-07-08 2018-01-11 Cognate Nutritionals, Inc. Nutritional mitiggation of the cns effects of traumatic brain injury
AU2017322708A1 (en) 2016-09-12 2019-03-21 University Of South Florida Neuroregeneration improved by ketone
DK3558280T3 (da) 2016-12-21 2023-08-21 Univ Kinderspital Beider Basel Forebyggelse og behandling af migræne

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Diet transiently improves migraine in two twin sisters: possible role of ketogenesis?;LORENZO等;《Functional Neurology》;20131231;第28卷(第4期);第305-308页 *
Ketone body therapy: from the ketogenic diet to the oral administration of ketone ester;Sami A. Hashim等;《 Journal of Lipid Research》;20140305;第55卷(第9期);第1818-1826页 *
Migraine improvement during short lasting ketogenesis: a proof-of-concept study;C. Di Lorenzo等;《EUROPEAN JOURNAL OF NEUROLOGY》;20140825;第22卷(第1期);第170-177页 *

Also Published As

Publication number Publication date
CA3046350A1 (en) 2018-06-28
JP7108320B2 (ja) 2022-07-28
BR112019012431A2 (pt) 2020-04-14
EP3558458B1 (en) 2023-10-18
US10792269B2 (en) 2020-10-06
MX2019006844A (es) 2019-08-16
US20180177753A1 (en) 2018-06-28
PT3558458T (pt) 2023-11-27
MY190308A (en) 2022-04-13
IL267540B (en) 2022-07-01
EP3558458A1 (en) 2019-10-30
WO2018118369A1 (en) 2018-06-28
CN110167637A (zh) 2019-08-23
KR102390608B1 (ko) 2022-04-25
CA3046350C (en) 2022-08-16
KR20190099465A (ko) 2019-08-27
EP3558458A4 (en) 2020-08-12
IL267540A (en) 2019-08-29
JP2020502250A (ja) 2020-01-23
ES2962879T3 (es) 2024-03-21
MX389468B (es) 2025-03-20
US20190117612A1 (en) 2019-04-25

Similar Documents

Publication Publication Date Title
CN110167637B (zh) 3-羟基丁酸甘油酯用于偏头痛症状管理
US11638702B2 (en) Glyceryl 3-hydroxybutyrates for traumatic brain injury
JP5362944B2 (ja) くも膜下出血の予後改善剤
CN104010634B (zh) 用于治疗神经系统病症的组合物
US9687462B2 (en) Sn-2-monoacylglycerols and lipid malabsorption
RU2501557C2 (ru) Новое применение жирной кислоты (жирных кислот) omega-3
CN106470675A (zh) 严重高甘油三酯血症的治疗
EP2726070A1 (en) Dha and epa in the reduction of oxidative stress
JP7608707B2 (ja) 近視進行抑制剤、機能性食品及び眼科用組成物
EP1498119B1 (en) Use of conjugated linoleic acid for treating colds
HK40012930B (en) Glyceryl 3-hydroxybutyrates for migraine symptom management
HK40012930A (en) Glyceryl 3-hydroxybutyrates for migraine symptom management
US20200085774A1 (en) Omega-3 Fatty Acid Composition for Preventing and/or Treating Cachexia
WO2005046668A1 (ja) 言語障害予防・治療剤
JPH0466528A (ja) 炎症性腸疾患用油脂組成物
HK40012461A (en) Glyceryl 3-hydroxybutyrates for traumatic brain injury
EP1147769A2 (de) Verwendung von mehrfach ungesättigten Fettsäuren, insbesondere Omega-3-Fettsäuren, zur Behandlung von Enuresis und Inkontinenz
US20180085382A1 (en) Compositions and methods for cognitive health and memory
NZ616554B2 (en) Compositions for the treatment of neurologic disorders

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40012930

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant